Avantium appoints bioplastics specialist

Jeffrey Kolstad joins as chief scientist from NatureWorks

Jeffrey Kolstad has joined Avantium as chief scientist, strengthening the Dutch firm’s team in developing next-generation bioplastics using its YXY technology.

Previously chief scientist at NatureWorks (formerly Cargill-Dow), Kolstad was one of the founding members of the team that developed and commercialised PLA (polylactic-acid), a bio-based polymer. He was also responsible for managing NatureWorks’ IP portfolio and strategy.

Prior to this Kolstad worked in the corporate research centres at Cargill and Amoco Oil Company.

You may also like

Research & Development

Avantium spins out pharma business

To create an independent business called Crystallics, specialising in solid state research
Research & Development

From lab to launch: transforming pharmaceutical formulation development with GEA’s CFC Lab Coater

A new generation of continuous film coating technology is giving R&D teams the speed, precision and scalability they need to take products from the laboratory to commercial production without the traditional bottlenecks
Manufacturing

Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target

BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
Drug Delivery

Neuland Laboratories to partner with LIR Life Sciences for transdermal GLP-1 development

The pair will work to advance LIR Life's novel cell-penetrating peptides for next-generation obesity therapies, looking to improve patient adherence and broaden access
Hi Tech Manufacturing

Hongene to support SiranBio siRNA candidate programme with CDMO services

The RNA specialist will support SiranBio's SA1211 programme, helping advance the siRNA candidate through its vertically integrated CDMO services to address the complex nature of the next-gen therapeutic
Research & Development

Reacta Healthcare announces expansion into Asia-Pacific and appoints Professor Gary Wing-Kin Wong to advisory board

Reacta Healthcare, a leading developer and manufacturer of pharmaceutical-grade oral food challenge (OFC) products for food allergy diagnostics, today announces the appointment of Professor Gary Wing-Kin Wong, internationally recognised paediatric allergy and respiratory disease expert and President-Elect of the World Allergy Organisation (WAO), to its Advisory Board, as the company accelerates new product development and expands its Asia-Pacific (APAC) footprint
Research & Development

BioDuro and CTI Technology partner to push forward preclinical drug development

The duo will combine their manufacturing experience and analytical capabilities to build an integrated platform spanning all the way from drug discovery to IND submission to accelerate the drug development path for clients
Subscribe now